Medicines Co. (MDCO) Cash Flow Statement

Click line-items for a historical chart and %

Cash flows from operating activities:
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	22.52M
Amortization of net premiums and discounts on available for sale securities
Unrealized foreign currency transaction losses (gain), net	-125K
Non-cash stock compensation expense	24.54M
Loss on disposal of fixed assets	1K
Deferred tax provision	-1.66M
Adjustment to contingent purchase price
Changes in operating assets and liabilities:
Accrued interest receivable	-13K
Accounts receivable	24.13M
Inventory	-14.08M
Prepaid expenses and other current assets	1.92M
Accounts payable	-17.27M
Accrued expenses	-49.11M
Deferred revenue	-5.76M
Other liabilities	-6.15M
Net cash provided by operating activities	-260.99M
Cash flows from investing activities:
Purchases of available for sale securities
Proceeds from maturities and sales of available for sale securities
Purchases of fixed assets	-920K
Adjustment to goodwill
Increase in restricted cash	-3.66M
Net cash provided by (used in) investing activities	423.3M
Cash flows from financing activities:
Proceeds from issuances of common stock, net	27.4M
Net cash provided by financing activities	65.69M
Effect of exchange rate changes on cash	-814K
Increase in cash and cash equivalents	227.18M
Cash and cash equivalents at beginning of period	373.17M
Cash and cash equivalents at end of period	600.36M
Supplemental disclosure of cash flow information:
Taxes paid	27K

Entities mentioned with MDCO